A Study to Compare SB12 (Proposed Eculizumab Biosimilar) to Soliris in Subjects With Paroxysmal Nocturnal Haemoglobinuria
Status:
Completed
Trial end date:
2021-10-21
Target enrollment:
Participant gender:
Summary
This is a randomised Phase III, double-blind, multicentre, cross-over study to compare the
efficacy, safety, pharmacokinetics, and immunogenicity between SB12 and Soliris® in subjects
with PNH.